Simon R. J. Taylor

Simon R. J. Taylor

Auto-generated profile, based on publicly available information

Simon R. J. Taylor

Moorfields Eye Hospital, London, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
MSMarc D. De Smet
Marc D. De Smet
STSimon R.J. Taylor
Simon R.J. Taylor
BBBahram Bodaghi
Bahram Bodaghi
EMElisabetta Miserocchi
Elisabetta Miserocchi
PMPhilip I. Murray
Philip I. Murray
SLSue Lightman
Sue Lightman

1 December 2014 in Ophthalmology
Verified
Journal Article
Closed access
ONOren Tomkins Netzer
Oren Tomkins Netzer
LTLazha Talat
Lazha Talat
ABAsaf Bar
Asaf Bar
ALAlbert Lula
Albert Lula
STSimon R.J. Taylor
Simon R.J. Taylor
SLSue Lightman
Sue Lightman

29 April 2009 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
STSimon R. J. Taylor
Simon R. J. Taylor
ASAlan D. Salama
Alan D. Salama
LJLavnish Joshi
Lavnish Joshi
CPCharles D. Pusey
Charles D. Pusey
SLSusan L. Lightman
Susan L. Lightman
Objective: To investigate the efficacy of rituximab in patients with refractory ophthalmic Wegener's granulomatosis (WG).Methods: Data from 10 consecutive patients with refractory ophthalmic WG treated with rituximab were retrospectively reviewed. In all patients, the ophthalmic disease was driving treatment decisions, and disease activity had persisted despite standard immunosuppressive treatment. Patients had refractory scleritis (n = 3), orbital granulomas causing optic nerve compromise (n = 4), or a combination of both conditions (n = 3). All patients had been treated with at least 3 different immunosuppressive agents, and 5 patients had previously been treated with tumor necrosis factor α blockade. Rituximab was administered intravenously in 2 doses, 2 weeks apart, in combination with standard treatment. Disease activity was monitored clinically by an interdisciplinary approach, including disease activity scoring, immunodiagnostics, and magnetic resonance imaging, as well as by corresponding reductions in the required dose of conventional medication.Results: A beneficial response to treatment with rituximab was seen in all 10 patients, including induction of clinical remission. In all patients, the peripheral blood B cell count fell to zero during treatment with rituximab. Titers of classic antineutrophil cytoplasmic antibodies fell in association with B cell counts, and this reduction was correlated with improved clinical findings.Conclusion: In contrast to previous observations, this study showed that treatment with rituximab was associated with clinical improvement in patients with refractory ophthalmic WG.

1 August 2014 in Ophthalmology
Verified
Journal Article
Closed access
ONOren Tomkins Netzer
Oren Tomkins Netzer
STSimon R.J. Taylor
Simon R.J. Taylor
ABAsaf Bar
Asaf Bar
ALAlbert Lula
Albert Lula
SYSatish Yaganti
Satish Yaganti
SLSue Lightman
Sue Lightman

1 June 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
STSimon R.J. Taylor
Simon R.J. Taylor
CTClare M. Turner
Clare M. Turner
JEJames I. Elliott
James I. Elliott
JMJohn McDaid
John McDaid
RHReiko Hewitt
Reiko Hewitt
FTFrederick Tam
Frederick Tam
The P2X7 receptor is a ligand-gated cation channel that is normally expressed by a variety of immune cells, including macrophages and lymphocytes. Because it leads to membrane blebbing, release of IL-1β, and cell death by apoptosis or necrosis, it is a potential therapeutic target for a variety of inflammatory diseases. Although the P2X7 receptor is usually not detectable in normal renal tissue, we previously reported increased expression of both mRNA and protein in mesangial cells and macrophages infiltrating the glomeruli in animal models of antibody-mediated glomerulonephritis. In this study, we used P2X7-knockout mice in the same experimental model of glomerulonephritis and found that P2X7 deficiency was significantly renoprotective compared with wild-type controls, evidenced by better renal function, a striking reduction in proteinuria, and decreased histologic glomerular injury. In addition, the selective P2X7 antagonist A-438079 prevented the development of antibody-mediated glomerulonephritis in rats. These results support a proinflammatory role for P2X7 in immune-mediated renal injury and suggest that the P2X7 receptor is a potential therapeutic target.

1 April 2009 in Ophthalmology
Verified
Journal Article
Closed access
STSimon R.J. Taylor
Simon R.J. Taylor
ZHZohar Habot-Wilner
Zohar Habot-Wilner
PPPatricio Pacheco
Patricio Pacheco
SLSue L. Lightman
Sue L. Lightman